Pharmacist - Physician Collaborative Approach to the Management of Metabolic Syndrome

University of Jordan

Status: Completed

Conditions: Metabolic Syndrome

Treatments: Other: Pharmaceutical care services

Study type: Interventional

Funder types: Other

Identifiers

NCT01099306

JUaym8071383

Details and patient eligibility

About

This study devised an experimental focused pharmaceutical care program, allowed a clinical pharmacist to work in a physician office to assess and manage patients' metabolic syndrome status and its individual components. This study described the clinical benefits of physician- clinical pharmacist interaction in achieving improved glycemic control, lipid and blood pressure measurements, involving medication, diet, physical activity and patient heath care counseling.

Full description

A single blinded prospective randomized controlled trial conducted in family medicine outpatients clinics in Jordan. The study enrolled 199 patients met the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATPIII) criteria for the diagnosis of MS upon the time of enrollment. Patients were randomized into: 110 participants into the intervention arm (pharmacist-physician collaborative approach) and 89 into the control arm (physician only team). Only patients in the intervention arm were provided pharmacist recommendations and pharmaceutical care counseling.

Enrollment: 199 patients

Sex: All

Ages: 32 to 88 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Meeting at least 3 of the 5 criteria for the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATPIII) for the diagnosis of Metabolic syndrome upon the time of enrollment. :

  1. Abdominal circumference >102 cm in males or >88 cm in females.
  2. HDL cholesterol < 40 mg/dl for males or < 50 mg/dl for females.
  3. Triglycerides ≥ 150 mg/dl.
  4. Blood pressure ≥ 130/85 mmHg or receiving hypertension treatment.
  5. Baseline glycemia ≥ 110 mg/dl.

Exclusion criteria

1. Patients with hypertensive urgency or emergency with BP more than (180/110).
2. Patients with recent stroke or myocardial infraction (within past 6 months).
3. Patients with Class III or IV Chronic heart Failure (CHF).
4. Patients with Unstable angina.
5. Patients with Serious renal or hepatic disease.
6. Pregnant patients.
7. Patients with Dementia or cognitive impairment.
8. If the patient is unable to provide informed written consent.

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

199 participants in 2 patient groups

intervention

Active Comparator group

Description:

pharmacist-physician collaborative approach to manage Metabolic syndrome

Treatment:

Other: Pharmaceutical care services

control

No Intervention group

Description:

physician only team to manage Metabolic syndrome